# E3 Breast Cancer Taxotere Combination

> **NCT00494481** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 64 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Vandetanib (ZD6474)
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00494481
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-06
- **Final completion:** 2009-01
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2016-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00494481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00494481, "E3 Breast Cancer Taxotere Combination". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00494481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*